| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥15.71B | ¥14.60B | +7.6% |
| Cost of Sales | ¥3.08B | ¥2.69B | +14.4% |
| Gross Profit | ¥12.63B | ¥11.90B | +6.1% |
| SG&A Expenses | ¥15.14B | ¥11.02B | +37.4% |
| Operating Income | ¥-2.51B | ¥882M | -384.7% |
| Non-operating Income | ¥63M | ¥87M | -27.6% |
| Non-operating Expenses | ¥196M | ¥80M | +145.0% |
| Ordinary Income | ¥-2.64B | ¥888M | -397.7% |
| Profit Before Tax | ¥-2.64B | ¥888M | -397.3% |
| Income Tax Expense | ¥-749M | ¥527M | -242.1% |
| Net Income | ¥-1.89B | ¥360M | -625.3% |
| Net Income Attributable to Owners | ¥-1.89B | ¥360M | -625.3% |
| Total Comprehensive Income | ¥-1.81B | ¥314M | -675.5% |
| Depreciation & Amortization | ¥158M | ¥161M | -1.9% |
| Interest Expense | ¥25M | ¥24M | +4.2% |
| Basic EPS | ¥-65.52 | ¥12.86 | -609.5% |
| Dividend Per Share | ¥12.50 | ¥12.50 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥22.86B | ¥23.87B | ¥-1.01B |
| Cash and Deposits | ¥8.67B | ¥9.16B | ¥-484M |
| Accounts Receivable | ¥4.32B | ¥5.04B | ¥-715M |
| Inventories | ¥6.89B | ¥6.31B | +¥579M |
| Non-current Assets | ¥9.77B | ¥8.78B | +¥988M |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥-2.12B | ¥35M | ¥-2.15B |
| Investing Cash Flow | ¥-365M | ¥-299M | ¥-66M |
| Financing Cash Flow | ¥2.00B | ¥-3.65B | +¥5.64B |
| Free Cash Flow | ¥-2.48B | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | -12.0% |
| Gross Profit Margin | 80.4% |
| Current Ratio | 102.8% |
| Quick Ratio | 71.8% |
| Debt-to-Equity Ratio | 2.48x |
| Interest Coverage Ratio | -100.44x |
| EBITDA Margin | -15.0% |
| Effective Tax Rate | 28.4% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +7.6% |
| Operating Income YoY Change | +46.7% |
| Ordinary Income YoY Change | +46.7% |
| Net Income Attributable to Owners YoY Change | +25.9% |
| Total Comprehensive Income YoY Change | -21.8% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 29.08M shares |
| Treasury Stock | 212K shares |
| Average Shares Outstanding | 28.87M shares |
| Book Value Per Share | ¥324.90 |
| EBITDA | ¥-2.35B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥12.50 |
| Year-End Dividend | ¥12.50 |
| Segment | Revenue | Operating Income |
|---|---|---|
| BioDirectValue | ¥13.84B | ¥-1.84B |
| BioFunctionalSeeds | ¥1.80B | ¥128M |
| BioMedical | ¥49M | ¥-137M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥68.00B |
| Operating Income Forecast | ¥1.50B |
| Ordinary Income Forecast | ¥1.50B |
| Net Income Attributable to Owners Forecast | ¥1.00B |
| Basic EPS Forecast | ¥34.64 |
| Dividend Per Share Forecast | ¥12.50 |
| Property, Plant & Equipment | ¥4.79B | ¥4.70B | +¥89M |
| Intangible Assets | ¥111M | ¥120M | ¥-9M |
| Goodwill | ¥62M | ¥71M | ¥-9M |
| Investment Securities | ¥2.64B | ¥2.45B | +¥193M |
| Total Assets | ¥32.62B | ¥32.65B | ¥-25M |
| Current Liabilities | ¥22.24B | ¥20.00B | +¥2.23B |
| Accounts Payable | ¥1.59B | ¥1.92B | ¥-335M |
| Short-term Loans | ¥13.90B | ¥11.40B | +¥2.50B |
| Non-current Liabilities | ¥1.01B | ¥1.10B | ¥-89M |
| Long-term Loans | ¥591M | ¥671M | ¥-80M |
| Total Liabilities | ¥23.25B | ¥21.10B | +¥2.14B |
| Total Equity | ¥9.38B | ¥11.55B | ¥-2.17B |
| Capital Stock | ¥2.04B | ¥2.04B | ¥0 |
| Capital Surplus | ¥1.81B | ¥1.81B | ¥0 |
| Retained Earnings | ¥5.44B | ¥7.69B | ¥-2.25B |
| Treasury Stock | ¥-195M | ¥-195M | ¥0 |
| Owners' Equity | ¥9.38B | ¥11.55B | ¥-2.17B |
| Working Capital | ¥621M | - | - |